Characterization of permeability, stability and anti-HIV-1 activity of decitabine and gemcitabine divalerate prodrugs

Antiviral Chemistry and Chemotherapy

Volumn 23, Issue 6, 2014, Pages 223-230

  Clouser, Christine L ^a,b   Bonnac, Laurent ^c   Mansky, Louis M ^a,b   Patterson, Steven E ^a,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; GEMCITABINE; PRODRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; AZACITIDINE; DECITABINE; DEOXYCYTIDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL PROLIFERATION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG PENETRATION; DRUG STABILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC50; IN VIVO STUDY; INTESTINE ABSORPTION; PRIORITY JOURNAL; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; BIOAVAILABILITY; CACO 2 CELL LINE; DRUG EFFECTS; HALF LIFE TIME; HEK293 CELL LINE; METABOLISM; PERMEABILITY; PH; PHYSIOLOGY;

ANTI-HIV AGENTS; AZACITIDINE; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CELL PROLIFERATION; DEOXYCYTIDINE; DRUG STABILITY; HALF-LIFE; HEK293 CELLS; HIV-1; HUMANS; HYDROGEN-ION CONCENTRATION; PERMEABILITY; PRODRUGS;

EID: 84889252941     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2682     Document Type: Article

References (45)

1. Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 1995; 69:5087–5094.
2. Dapp MJ, Patterson SE, Mansky LM. Back to the future: revisiting HIV-1 lethal mutagenesis. Trends Microbiol 2013; 21:56–62.
3. Loeb LA, Essigmann JM, Kazazi F, et al. Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc Natl Acad Sci U S A 1999; 96:1492–1497.
4. Clouser CL, Patterson SE, Mansky LM. Exploiting drug repositioning for discovery of a novel HIV combination therapy. J Virol 2010; 84:9301–9309.
5. Tohyama K. Utility of DNA methyltransferase inhibitors for the treatment of myelodysplastic syndromes. Curr Pharm Des 2012; 18:3190–3197.
6. Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Ann Oncol 2006; 17 Suppl 5:v7–v12.
7. Christman JK. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002; 21:.5483–5495
8. Jüttermann R, Li E, Jaenisch R. Toxicity of 5-aza-2′- deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci U S A 1994; 91:11797–11801.
9. Heinemann V, Xu YZ, Chubb S, et al. Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation. Cancer Res 1992; 52:533–539.
10. Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Ann Oncol 2006; 17:v7–v12.
11. Plunkett W, Huang P, Xu YZ, et al. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995; 22:3–10.
12. Clouser CL, Holtz CM, Mullett M, et al. Activity of a novel combined antiretroviral therapy of gemcitabine and decitabine in a mouse model for HIV-1. Antimicrob Agents Chemother 2012; 56:1942–1948.
13. Chattopadhyay SK, Morse HC, III, Makino M, Ruscetti SK, Hartley JW. Defective virus is associated with induction of murine retrovirus-induced immunodeficiency syndrome. Proc Natl Acad Sci U S A 1989; 86:3862–3866.
14. Chattopadhyay SK, Sengupta DN, Fredrickson TN, Morse HC, III, Hartley JW. Characteristics and contributions of defective, ecotropic, and mink cell focus-inducing viruses involved in a retrovirus-induced immunodeficiency syndrome of mice. J Virol 1991; 65:4232–4241.
15. Mosier DE, Yetter RA, Morse HC, III. Functional T lymphocytes are required for a murine retrovirus-induced immunodeficiency disease (MAIDS). J Exp Med 1987; 165:1737–1742.
16. Abbruzzese JL, Grunewald R, Weeks EA, et al. A Phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 9:491–498.
17. Moysan E, Bastiat G, Benoit JP. Gemcitabine versus modified gemcitabine: a review of several promising chemical modifications. Mol Pharm 2013; 10:430–444.
18. Francia G, Shaked Y, Hashimoto K, et al. Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis. Mol Cancer Ther 2012; 11:680–689.
19. Koolen SL, Witteveen PO, Jansen RS, et al. Phase I study of oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors. Clin Cancer Res 2011; 17:6071–6082.
20. Lavelle D, Saunthararajah Y, Vaitkus K, et al. S110, a novel decitabine dinucleotide, increases fetal hemoglobin levels in baboons (P. anubis). J Transl Med 2010; 8:92–99.
21. Tao XM, Wang JC, Wang JB, et al. Enhanced anticancer activity of gemcitabine coupling with conjugated linoleic acid against human breast cancer in vitro and in vivo. Eur J Pharm Biopharm 2012; 82:401–409.
22. Lavelle D, Vaitkus K, Ling Y, et al. Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine. Blood 2012; 119:1240–1247.
23. Beumer JH, Eiseman JL, Parise RA, et al. Modulation of gemcitabine (2′,2′-difluoro-2′-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine. Clin Cancer Res 2008; 14:3529–3535.
24. Harrington RD, Geballe AP. Cofactor requirement for human immunodeficiency virus type 1 entry into a CD4- expressing human cell line. J Virol 1993; 67:5939–5947.
25. Vodicka MA, Goh WC, Wu LI, et al. Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses. Virology 1997; 233:193–198.
26. Dapp MJ, Clouser CL, Patterson S, Mansky LM. 5-Azacytidine can induce lethal mutagenesis in human immunodeficiency virus type 1. J Virol 2009; 83:11950–11958.
27. Lin KT, Momparler RL, Rivard GE. High-performance liquid chromatographic analysis of chemical stability of 5-aza-2′-deoxycytidine. J Pharm Sci 1981; 70:1228–1232.
28. Liu Z, Marcucci G, Byrd JC, et al. Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2′- deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method. Rapid Commun Mass Spectrom 2006; 20:1117–1126.
29. Press B, Di Grandi D. Permeability for intestinal absorption: Caco-2 assay and related issues. Curr Drug Metab 2008; 9:893–900.
30. Ziemba A, Hayes E, Freeman BB, III, Ye T, Pizzorno G. Development of an oral form of azacytidine: 2′3′5′triacetyl- 5-azacytidine. Chemother Res Pract 2011; 2011:965826–965835.
31. Evans DF, Pye G, Bramley R, et al. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut 1988; 29:1035–1041.
32. Fallingborg J. Intraluminal pH of the human gastrointestinal tract. Dan Med Bull 1999; 46:183–196.
33. Rogstad DK, Herring JL, Theruvathu JA, et al. Chemical decomposition of 5-aza-2′-deoxycytidine (decitabine): kinetic analyses and identification of products by NMR, HPLC, and mass spectrometry. Chem Res Toxicol 2009; 22:1194–1204.
34. Zhao C, Xue X, Li G, et al. Synthesis and biological evaluation of oral prodrugs based on the structure of gemcitabine. Chem Biol Drug Des 2012; 80:479–488.
35. Obajimi O, Melera PW. The depletion of cellular ATP by AG2034 mediates cell death or cytostasis in a hypoxanthine-dependent manner in human prostate cancer cells. Cancer Chemother Pharmacol 2008; 62:215–226.
36. Leone G, Teofili L, Voso MT, Lubbert M. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica 2002; 87:1324–1341.
37. Pinto A, Zagonel V. 5-Aza-2′-deoxycytidine (decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends. Leukemia 1993; 7 Suppl 1:51–60.
38. Carmichael J, Fink U, Russell RC, et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996; 73:101–105.
39. Greggs WM, III, Clouser CL, Patterson SE, Mansky LM. Discovery of drugs that possess activity against feline leukemia virus. J Gen Virol 2012; 93:900–905.
40. Clouser CL, Holtz CM, Mullett M, et al. Analysis of the ex vivo and in vivo antiretroviral activity of gemcitabine. PLoS ONE 2011; 6:e15840.
41. Denisova OV, Kakkola L, Feng L, et al. Obatoclax, saliphenylhalamide, and gemcitabine inhibit influenza a virus infection. J Biol Chem 2012; 287:35324–35332.
42. Song X, Lorenzi PL, Landowski CP, et al. Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport. Mol Pharm 2005; 2:157–167.
43. Imai T, Ohura K. The role of intestinal carboxylesterase in the oral absorption of prodrugs. Curr Drug Metab 2010; 11:793–805.
44. Liederer BM, Borchardt RT. Enzymes involved in the bioconversion of ester-based prodrugs. J Pharm Sci 2006; 95:1177–1195.
45. Satoh T, Hosokawa M. The mammalian carboxylesterases: from molecules to functions. Annu Rev Pharmacol Toxicol 1998; 38:257–288.